A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug. The studies presented a number of critical challenges to the PRA project team. Through teamwork and strategic planning, PRA developed plans that helped us reach the client’s milestones and resulted in successful site activations and first patient in.
Creating Solutions to Ensure Endpoint Protection in Challenging Rare Disease Trial
The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.